Background Multiple sclerosis (MS) is a chronic neuroinflammatory disease with heterogeneous clinical presentations and progression rates that pose challenges to its management. Identifying prognostic biomarkers is crucial for individualized treatment approaches. Interleukin-10 (IL-10) has emerge…